Oncolytics Biotech, Inc.

Twitter LinkedIn
  • Home
  • About
    • Our Company
    • Management Team
    • Board of Directors
  • Technology
    • What is Pelareorep?
    • What Does Pelareorep Do?
    • Delivery
    • Intellectual Property
    • Posters & Publications
    • Manufacturing
  • Clinical Trials
    • Clinical Development Plan
    • Collaborators
    • Pipeline
  • Media
    • Press Releases
    • Insights
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Filings & Financials
    • Corporate Governance
    • FAQs
    • Email Alerts
    • IR Contacts
  • Contact
  • Careers

News

Media

Media

  • Press Releases
  • Insights
Dec 10, 2021

Oncolytics Biotech® Presents Positive Interim Safety Update from Phase 2 Triple-Negative Breast Cancer Trial at the 2021 San Antonio Breast Cancer Symposium

Nov 19, 2021

Oncolytics Biotech® to Present Phase 2 Triple-Negative Breast Cancer Trial Update at the 2021 San Antonio Breast Cancer Symposium

Nov 5, 2021

Oncolytics Biotech® Reports 2021 Third Quarter Development Highlights and Financial Results

Nov 3, 2021

Oncolytics Biotech® Doses First Patient in Phase 1/2 GOBLET Study Evaluating Pelareorep-anti-PD-L1 Combination Therapies in Gastrointestinal Cancers

Oct 19, 2021

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights

Oct 14, 2021

Oncolytics Biotech®Partner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer

Sep 20, 2021

Oncolytics Biotech® Announces Preclinical Data Demonstrating the Synergistic Immunotherapeutic Effects of Pelareorep Combined with Radiotherapy

Aug 6, 2021

Oncolytics Biotech® Reports 2021 Second Quarter Development Highlights and Financial Results

Aug 6, 2021

Oncolytics Biotech® to Participate in Virtual Fireside Chat at the Canaccord Genuity 41st Annual Growth Conference

Jul 22, 2021

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights

    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...59
    © 2023 Oncolytics Biotech, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap